---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025793"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2026-08-05T12:02:32+00:00"
generated_at: "2026-08-05T12:05:15.104325+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# UroGen Q2 2026: ZUSDURI revenue $50.4M (+73% QoQ); net loss narrows to $14.4M

## Summary
- Total revenue $72.5M (Q2 2026) vs $24.2M (Q2 2025), driven by ZUSDURI launch.
- ZUSDURI net product revenue $50.4M, 73% QoQ growth; 1,444 activated sites, 452 prescribers.
- JELMYTO revenue $22.0M (Q2 2026) vs $24.2M (Q2 2025); FY guidance $97-101M.
- Net loss $14.4M ($0.28/share) vs $49.9M ($1.05) in Q2 2025; cash $108.0M.
- UGN-103 NDA on track for Q3 2026; new patent allowance extends ZUSDURI protection to July 2044.

## SEC filing metadata
- accession: 0001437749-26-025793
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2026-08-05T12:02:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/0001437749-26-025793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/urgn20260730_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025793
- JSON: https://secwatch.observer/filing/0001437749-26-025793.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.